Pacific Biosciences Announces Ten-Unit Sequel System Order for Annoroad

MENLO PARK, Calif., March 27, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced a purchase order for 10 PacBio® Sequel® Systems that are expected to be installed at Annoroad’s designated facility within the next several months, enhancing Annoroad’s large-scale genomic service capabilities across various fields... Read more

Horizon Discovery introduces whole human genome arrayed libraries to support CRISPR activation screening

Location: Cambridge 26/03/2018 First-to-market Edit-R CRISPRa arrayed crRNA libraries enable native gene overexpression for high-throughput gain-of-function screening Available as small gene families, bespoke collections, the druggable genome, or human genome-wide collection Cambridge, UK, 26 March 2018: Horizon Discovery (LSE: HZD) (“Horizon” or the “Company”), a global leader in the application of gene editing and gene modulation... Read more

Pacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford Nanopore

MENLO PARK, Calif., March 22, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced that Judge Leonard P. Stark of the U.S. District Court for the District of Delaware denied a motion to dismiss filed on December 14, 2017 by Oxford Nanopore Technologies, Inc., a wholly-owned... Read more

Bio-Techne Expands RNAscope® ISH Automation – Facilitating Drug Discovery and Development

New and updated assays increase application areas and improve performance MINNEAPOLIS, March 21, 2018 /PRNewswire/ — Bio-Techne has expanded the automation capabilities of its popular Advanced Cell Diagnostics (ACD)-branded RNAscope® in situ hybridization (ISH) technology with the launch of several new and updated assays. The developments increase both access to, and use of, RNAscope and improve overall robustness and ease-of-use.... Read more

Oxford Nanopore announces £100 million ($140M) fundraising from global investors

Tue 20th March 2018 Funding will support new manufacturing facility, commercial expansion, and development of new innovative products. Oxford, UK. Oxford Nanopore Technologies Ltd, the company behind the only portable real-time DNA/RNA sequencer, MinION, has raised £100M ($140M) in new investment. Funds were raised from global investors including GIC (Singapore), CCB International (CCBI, China), Hostplus (Australia),... Read more

Quanterix Corporation and DestiNA Genomics to Collaborate in Effort to Transform microRNA Biomarker Detection

Collaboration offers potential for PCR-free microRNA biomarker detection with high-specificity and ultra-sensitivity March 20, 2018 06:00 AM Pacific Daylight Time LEXINGTON, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced a collaboration with DestiNA Genomics, a manufacturer of patented reagents for nucleic acid detection.... Read more

Human Longevity, Inc. Hires Former Ancestry Executive, Scott Sorensen, As New Chief Technology Officer

INDUSTRY LEADER BRINGS 25 YEARS OF EXPERTISE IN SOFTWARE PRODUCTS AND SERVICES TO HELP HLI SCALE BUSINESS SAN DIEGO, March 19, 2018 /PRNewswire/ — Human Longevity, Inc. (HLI) – the genomics-powered health intelligence company – announced today that Scott Sorensen is joining the leadership team as Chief Technology Officer, reporting to J. Craig Venter, Ph.D., Co-Founder, Chairman and CEO. Sorensen joins... Read more

Luna DNA Expands Leadership and Advisory Board, Adding New Pedigree From Illumina

Three industry leaders join company ranks to drive genomic discovery SAN DIEGO, March 19, 2018 /PRNewswire/ — 9:30 a.m. PT — Luna DNA, the first community owned genomic and medical research database, today announced the addition of three new members to its leadership team. The key hires in the VP of marketing and VP of business strategy and operation... Read more

CMS and Commercial Insurers Extend Coverage of Oncomine Dx Target Test to more than 160 Million U.S. Lives

CMS and Commercial Insurers Extend Coverage of Oncomine Dx Target Test to more than 160 Million U.S. Lives Payors reimburse first NGS, FDA-approved test for non-small cell lung cancer to expedite targeted therapy selection for patients CARLSBAD, Calif., March 19, 2018 /PRNewswire/ — Thermo Fisher Scientific today announced its Oncomine Dx Target Test has been approved for... Read more

Thermo Fisher Scientific Acquires IntegenX, Provider of Leading Rapid DNA Technology for Human Identification

Thermo Fisher Scientific Acquires IntegenX, Provider of Leading Rapid DNA Technology for Human Identification CARLSBAD, Calif., March 16, 2018 /PRNewswire/ — Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has acquired IntegenX Inc., which provides a rapid DNA platform for use in forensics and law enforcement applications. IntegenX products significantly... Read more